Cover Image
市場調查報告書

醫藥品產業領導者系列 - 生物相似藥製造商前25名公司 2017年∼2027年

Pharma Leader Series - 25 Top Biosimilar Drug Manufacturers 2017-2027: And Other Rising Companies - A Market Report Assessing Developers and Producers of Competitor Biologics

出版商 Visiongain Ltd 商品編碼 288682
出版日期 內容資訊 英文 233 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
醫藥品產業領導者系列 - 生物相似藥製造商前25名公司 2017年∼2027年 Pharma Leader Series - 25 Top Biosimilar Drug Manufacturers 2017-2027: And Other Rising Companies - A Market Report Assessing Developers and Producers of Competitor Biologics
出版日期: 2017年08月31日 內容資訊: 英文 233 Pages
簡介

本報告以全球生物相似藥市場為研究主題,提供市場概要與預測,主要產品概要,各國趨勢,及前25家企業簡介等彙整資料。

第1章 報告概要

第2章 生物相似藥:全球市場的預測

  • 生技藥品和生物相似藥的簡介
    • 生技藥品:定義和概要
    • 生物相似藥:定義和概要
    • 生物相似藥和仿製藥的差異
  • 全球生物相似藥市場
  • 全球生物相似藥市場整體收益預測
  • 生物相似藥:可能性的實現,推動市場的要素
  • 生物相似藥:阻礙市場的要素

第3章 主要生技藥品、生物相似藥產品:概要

  • Humira:產品概要
  • Remicade:產品概要
  • Enbrel:產品概要
  • Aranesp:產品概要
  • Rituxan:產品概要

第4章 生物相似藥主要製造商:美國,西歐,以色列

  • Sandoz
  • Teva Pharmaceuticals
  • Hospira (Pfizer)
  • STADA Arzneimittel
  • Mylan
  • 其他生物相似藥製造商:美國
    • Impax Laboratories Inc.
    • Bristol-Myers Squibb
    • Merck. Co.
    • Eli Lilly
  • 其他生物相似藥製造商:歐洲
    • BioXpress Therapeutics
    • Medice Arzneimittel Putter GmbH. Co. KG
    • Finox Biotech

第5章 生物相似藥主要製造商:中國

  • S3Bio
  • Qilu Pharmaceutical
  • Shanghai Fosun Pharmaceuticals
  • Tonghua Dongbao
  • Beijing ShuangLu Pharmaceutical
  • 其他生物相似藥製造商
    • Shanghai CP Guojian
    • Zhejiang Hisun
    • Innovent Biologics
    • Shanghai Celgen Biopharmaceutical

第6章 生物相似藥主要製造商:印度

  • Biocon
  • Dr. Reddy's Laboratories
  • Wockhardt
  • Zydus Cadila
  • Ranbaxy (Sun Pharma)
  • Reliance Life Sciences
  • Intas Biopharmaceuticals
  • 其他生物相似藥製造商
    • Emcure Pharmaceuticals
    • Shreya Life Sciences
    • Cipla
    • Shantha Biotechnics

第7章 生物相似藥主要製造商:南美

  • Probiomed
  • Biosidus
  • Amega Biotech
  • 其他生物斑點:企業概要、分析製造商
    • Bionovis
    • Orygen Biotecnologia
    • Recepta

第8章 生物相似藥主要製造商:其他地區

  • Celltrion
  • LG Life Sciences
  • Dong-A
  • Bioton
  • Biocad
  • 其他生物相似藥製造商
    • Gedeon-Richter
    • Egis Pharmaceuticals
    • JCR製藥
    • 日本化藥
    • Fuji Film Kyowa Kirin Biologics
    • 第一三共

第9章 生物相似藥市場定性分析

  • SWOT分析
  • STEP分析

第10章 結論

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0231

Who Are the Leaders in the Emerging Biosimilar Drugs Market? Visiongain's New Analysis Gives Company Assessments, Discussions and Predictions

Where are companies in the Biosimilar market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead

Our 233-page report provides 126 tables, charts, and graphs, giving a clear view on companies in the biosimilar market. Who are the most important and promising biosimilar drug companies? And what are their sales potentials? Discover this information in our updated report, which analyses 25 leading developers, producers and marketers of biosimilars. The report also covers other firms, including big pharma companies entering that industry.

Molecules giving rise to biosimilars - explore where progress occurs

Our report discusses biosimilar competition for these five therapeutic agents - products and research and development:

  • Adalimumab
  • Infliximab
  • Etanercept
  • Darbepoetin alpha
  • Rituximab.

In particular, our report analyses 25 leading biosimilar specialists worldwide. First of all, Chapter 4 gives profiles of leading biosimilar companies based in the US, Western Europe and Israel:

  • Hospira (Pfizer)
  • Mylan
  • Sandoz (Novartis)
  • STADA Arzneimittel
  • Teva Pharmaceutical Industries

Chapter 5 profiles leading companies in China:

  • 3SBio
  • Beijing ShuangLu Pharmaceutical Co.
  • Qilu Pharmaceutical
  • Shanghai Fosun Pharmaceutical Group
  • Tonghua Dongbao Pharmaceutical Co.

Chapter 6 profiles leading companies in India:

  • Biocon
  • Dr. Reddy's Laboratories
  • Intas Biopharmaceuticals
  • Ranbaxy (Sun Pharma)
  • Reliance Life Sciences
  • Wockhardt
  • Zydus Cadila

image1

Chapter 7 profiles leading companies in Latin America:

  • Amega Biotech
  • Biosidus
  • Probiomed

Chapter 8 profiles leading companies in the rest of the world:

  • Biocad
  • Bioton
  • Celltrion
  • Dong-A
  • LG Life Sciences

Our report also reviews 25 other companies rising in importance. See what is possible from 2017, discovering what leading companies do and their commercial outlooks.

With our report, you will see who and what shapes the biosimilars industry, including policies, regulatory concerns and other forces influencing those companies and their market, affecting its revenues and profits. Discover what the future holds for leading organisations.

How the 25 Top Biosimilar Drug Manufacturers report helps you

In summary, our 233-page report provides you with the following knowledge:

  • Profiles of 25 leading biosimilar companies and other relevant firms - assess products, results, strategies, technologies and outlooks, also gaining company level revenue forecasting for five leading producers' biosimilar drug sales
  • R&D for biosimilars - see activities by company, finding what goes on in that industry, investigating its technological and commercial potentials
  • Competition and opportunities - explore what affects the biosimilars market, finding what shapes its future, especially prospects for developing business

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Visiongain's study is for everybody needing commercial analyses for the leading companies in the Biosimilar market. You will find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Overview of the Top Biosimilar Drug Manufacturers
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by This Analytical Study
  • 1.5 Who is This Report For?
  • 1.6 Methodology
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2. Biosimilar Drugs: World Market Forecast, 2017-2027

  • 2.1 Introduction to Biologics and Biosimilars
    • 2.1.1 Biologic Drugs Definition and Overview
    • 2.1.2 Biosimilars Drugs Definition and Overview
    • 2.1.3 How do Biosimilars Differ from Generics?
  • 2.2 The World Biosimilar Market, 2017-2027
  • 2.3 Overall World Biosimilars Revenue Forecast, 2017-2027
  • 2.4 Biosimilars - Realising their Potential, Market Drivers
    • 2.4.1 Biosimilar Approval Pathways and Regulations
    • 2.4.2 India Releases New Biosimilar Development Guidelines
    • 2.4.3 Russia: Lack of Regulatory Framework Works Well in the Short Term
    • 2.4.4 'Pharma 2020' Initiative
    • 2.4.5 South Korean Market has benefitted from Early Biosimilar Guidelines
    • 2.4.6 Chinese FDA Publishes Finalised Biosimilar Guidelines in 2016
    • 2.4.7 Brazil: ANVISA's Biosimilar Regulations Are Similar the EMA's
    • 2.4.8 The Outlook for Biosimilar mAbs in the EU
    • 2.4.9 The Outlook for Biosimilar mAbs in Japan
    • 2.4.10 Emerging Markets for Biosimilars
    • 2.4.11 Start-up Pressure on Market Leaders
    • 2.4.12 The Patent Cliff for Biologics
  • 2.5 Biosimilars: Market Restraints
    • 2.5.1 Market Fragmentation for Biosimilar Products
    • 2.5.2 Innovative Biologics - Rendering Biosimilars Useless?
    • 2.5.3 Biobetters - A Growing Threat
    • 2.5.4 BREXIT and Trump Election - A Rising Political Threat

3. Leading Biologic & Biosimilar Products: Overview, 2017

  • 3.1 Humira: Product Overview
    • 3.1.1 Adalimumab Biosimilars - Zydus Cadila
    • 3.1.2 Adalimumab Biosimilars - Amgen-Actavis
    • 3.1.3 Adalimumab Biosimilars - Sandoz
    • 3.1.4 Adalimumab Biosimilars - Momenta Pharmaceuticals
    • 3.1.5 Adalimumab Biosimilars - Pfizer
    • 3.1.6 Adalimumab Biosimilars - Boehringer Ingelheim
  • 3.2 Remicade: Product Overview
    • 3.2.1 Infliximab Biosimilar - Epirus Pharmaceuticals & Ranbaxy
    • 3.2.2 Infliximab Biosimilar - Celltrion & Hospira & Alvogen
  • 3.3 Enbrel: Product Overview
    • 3.3.1 Etanercept Biosimilar - Cipla & Shanghai CP Guojian
    • 3.3.2 Etanercept Biosimilar - Daiichi Sankyo & Coherus Biosciences
  • 3.4 Aranesp: Product Overview
    • 3.4.1 Darbepoetin Alpha Biosimilar - Dr. Reddy's Laboratories
    • 3.4.2 Darbepoetin Alpha Biosimilar - Cipla & Hetero Drugs Limited
    • 3.4.3 Darbepoetin Alpha Biosimilar - Hospira
  • 3.5 Rituxan: Product Overview
    • 3.5.1 Rituximab Biosimilar - Sandoz
    • 3.5.2 Rituximab Biosimilar - Amgen
    • 3.5.3 Rituximab Biosimilar - Boehringer Ingelheim
    • 3.5.4 Rituximab Biosimilar - Dr. Reddy's Laboratories
    • 3.5.5 Rituximab Biosimilar - Pfizer
    • 3.5.6 Rituximab Biosimilar - Difficulties Seen in Trials

4. Leading Biosimilar Manufacturers in the United States, Western Europe and Israel, 2017

  • 4.1 Sandoz - Company Overview & Analysis
    • 4.1.1 Sandoz Biosimilar Products
    • 4.1.2 Sandoz Biosimilars Market Forecast, 2017-2027
    • 4.1.3 Sandoz Biosimilars R&D Pipeline & Future Outlook
  • 4.2 Teva Pharmaceuticals - Company Overview & Analysis
    • 4.2.1 Teva Biosimilar Products
    • 4.2.2 Teva Biosimilar Market Forecast, 2017-2027
    • 4.2.3 Teva Biosimilar Pipeline & Future Outlook
  • 4.3 Hospira (Pfizer) - Company Overview & Analysis
    • 4.3.1 Hospira Biosimilar Products
    • 4.3.2 Hospira Biosimilars Pipeline & Future Strategies
  • 4.4 STADA Arzneimittel - Company Overview & Analysis
    • 4.4.1 STADA Biosimilar Products
    • 4.4.2 STADA Biosimilars Pipeline & Future Outlook
  • 4.5 Mylan - Company Biosimilar & Analysis
    • 4.5.1 Mylan Biosimilar Products
    • 4.5.2 Mylan Biosimilar Market Forecast, 2017-2027
    • 4.5.3 Mylan Biosimilars Pipeline & Future Outlook
  • 4.6 Other Biosimilars Companies in the US
    • 4.6.1 Impax Laboratories Inc. - Company Overview & Analysis
    • 4.6.2 Bristol-Myers Squibb - Company Overview & Analysis
    • 4.6.3 Merck & Co. - Company Overview & Analysis
    • 4.6.4 Eli Lilly - Company Overview & Analysis
  • 4.7 Other Biosimilar Companies in Europe
    • 4.7.1 BioXpress Therapeutics - Company Overview & Analysis
    • 4.7.2 Medice Arzneimittel Pütter GmbH & Co. KG - Company Overview & Analysis
    • 4.7.3 Finox Biotech - Company Overview & Analysis

5. Leading Biosimilar Manufacturers in China, 2016

  • 5.1 S3Bio - Company Overview & Analysis
    • 5.1.1 3SBio Biosimilar Products
    • 5.1.2 3SBio Biosimilars Market Forecast, 2017-2027
    • 5.1.3 3SBio Biosimilars Pipeline & Future Outlook
  • 5.2 Qilu Pharmaceutical - Company Overview & Analysis
    • 5.2.1 Qilu Pharmaceutical Biosimilar Products
    • 5.2.2 Qilu Pharmaceutical Biosimilars Pipeline & Future Outlook
  • 5.3 Shanghai Fosun Pharmaceuticals - Company Overview & Analysis
    • 5.3.1 Shanghai Fosun Pharmaceuticals Biosimilar Products
    • 5.3.2 Shanghai Fosun Pharmaceuticals Biosimilars Pipeline & Future Strategy
  • 5.4 Tonghua Dongbao - Company Overview & Analysis
    • 5.4.1 Tonghua Dongbao Biosimilar Products
    • 5.4.2 Tonghua Dongbao Biosimilars Pipeline & Future Strategies
  • 5.5 Beijing ShuangLu Pharmaceuticals - Company Overview & Analysis
    • 5.5.1 Beijing ShuangLu Pharmaceuticals Biosimilar Products
    • 5.5.2 Beijing ShuangLu Pharmaceutical Biosimilars Pipeline & Future Outlook
  • 5.6 Other Biosimilars Companies in China
    • 5.6.1 Shanghai CP Guojian - Company Overview & Analysis
    • 5.6.2 Zhejiang Hisun - Company Overview & Analysis
    • 5.6.3 Innovent Biologics - Company Overview & Analysis
    • 5.6.4 Shanghai Celgen Biopharmaceutical - Company Overview & Analysis

6. Leading Biosimilar Manufacturers in India, 2016

  • 6.1 Biocon - Company Overview & Analysis
    • 6.1.1 Biocon Biosimilar Products
    • 6.1.2 Biocon Biosimilars Market Forecast, 2017-2027
    • 6.1.3 Biocon Biosimilars Pipeline & Future Outlook
  • 6.2 Dr. Reddy's Laboratories - Company Overview & Analysis
    • 6.2.1 Dr. Reddy's Laboratories Biosimilar Products
    • 6.2.2 Dr. Reddy's Laboratories Biosimilars Pipeline & Future Outlook
  • 6.3 Wockhardt - Company Overview & Analysis
    • 6.3.1 Wockhardt Biosimilar Products
    • 6.3.2 Wockhardt Biosimilars Pipeline & Future Outlook
  • 6.4 Zydus Cadila - Company Overview & Analysis
    • 6.4.1 Zydus Cadila Biosimilar Products
    • 6.4.2 Zydus Cadila Biosimilars Pipeline & Future Outlook
  • 6.5 Ranbaxy (Sun Pharma) - Company Overview & Analysis
    • 6.5.1 Ranbaxy Biosimilar Products
    • 6.5.2 Ranbaxy Biosimilars Pipeline & Future Outlook
  • 6.6 Reliance Life Sciences - Company Overview & Analysis
    • 6.6.1 Reliance Life Sciences Biosimilar Products
    • 6.6.2 Reliance Life Sciences Biosimilars Pipeline & Future Outlook
  • 6.7 Intas Biopharmaceuticals - Company Overview & Analysis
    • 6.7.1 Intas Biopharmaceuticals Biosimilar Products
    • 6.7.2 Intas Biopharmaceuticals Biosimilars Pipeline & Future Outlook
  • 6.8 Other Indian Biosimilars Companies
    • 6.8.1 Emcure Pharmaceuticals - Company Overview & Analysis
    • 6.8.2 Shreya Life Sciences - Company Overview & Analysis
    • 6.8.3 Cipla - Company Overview & Analysis
    • 6.8.4 Shantha Biotechnics - Company Overview & Analysis

7. Leading Biosimilar Manufacturers in Latin America, 2016

  • 7.1 Probiomed - Company Overview & Analysis
    • 7.1.1 Probiomed Biosimilar Products
    • 7.1.2 Probiomed Biosimilars Pipeline & Future Strategies
  • 7.2 Biosidus - Company Overview & Analysis
    • 7.2.1 Biosidus Biosimilar Products
    • 7.2.2 Biosidus Biosimilars Pipeline & Future Strategies
  • 7.3 Amega Biotech - Company Overview and Analysis
    • 7.3.1 Amega - Biosimilar Products
    • 7.3.2 Amega Biotech Biosimilars Pipeline & Future Strategies
  • 7.4 Other Biosimilars Companies in South America
    • 7.4.1 Bionovis - Company Overview & Analysis
    • 7.4.2 Orygen Biotecnologia - Company Overview & Analysis
    • 7.4.3 Recepta - Company Overview & Analysis

8. Leading Biosimilar Manufacturers in the Rest of the World, 2016

  • 8.1 Celltrion - Company Overview & Analysis
    • 8.1.1 Celltrion Biosimilar Products
    • 8.1.2 Celltrion Biosimilars Pipeline & Future Strategies
  • 8.2 LG Life Sciences - Company Overview & Analysis
    • 8.2.1 LG Life Sciences Biosimilar Products
    • 8.2.2 LG Life Science Biosimilars Pipeline & Future Strategies
  • 8.3 Dong-A - Company Overview & Analysis
    • 8.3.1 Dong-A Biosimilar Products
    • 8.3.2 Dong-A Biosimilars Pipeline & Future Strategies
  • 8.4 Bioton - Company Overview & Analysis
    • 8.4.1 Bioton's Biosimilar Products
    • 8.4.2 Bioton's Biosimilars Pipeline & Future Strategies
  • 8.5 Biocad - Company Overview & Analysis
    • 8.5.1 Biocad's Biosimilar Products
    • 8.5.2 Biocad's Biosimilars Pipeline & Future Strategies
  • 8.6 Other Biosimilars Companies in the RoW
    • 8.6.1 Gedeon-Richter - Company Overview & Analysis
    • 8.6.2 Egis Pharmaceuticals - Company Overview & Analysis
    • 8.6.3 JCR Pharmaceuticals - Company Overview & Analysis
    • 8.6.4 Nippon Kayaku - Company Overview & Analysis
    • 8.6.5 Fujifilm Kyowa Kirin Biologics - Company Overview & Analysis
    • 8.6.6 Daiichi Sankyo - Company Overview & Analysis

9. Qualitative Analysis of Biosimilars Market: 2017-2027

  • 9.1 SWOT Analysis of the Global Biosimilars Industry and Market: 2017-2027
    • 9.1.1 Strengths
    • 9.1.2 Weaknesses
    • 9.1.3 Opportunities
    • 9.1.4 Threats
  • 9.2 STEP Analysis of the Global Biosimilars Industry and Market: 2017 -2027
    • 9.2.1 Social Factors
    • 9.2.2 Technological Factors
    • 9.2.3 Economic Factors
    • 9.2.4 Political Factors

10. Conclusions

  • 10.1 Market Leaders Among Biosimilar Manufacturers
  • 10.2 Will Sandoz Retain its Position as Market Leader?
  • 10.3 Which Companies Are Best Placed to Lead in Future?
  • 10.4 Big Pharma Companies Will Try Gain Market Entry
  • 10.5 Contribution of Chinese and Indian Companies will Grow
  • 10.6 Strong R&D Pipeline - Driver for Growth
  • 10.7 Concluding Remarks
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Figures

  • Figure 1.1 Biosimilars Market Segmentation, 2016
  • Figure 2.1 Global Biosimilar Market: Revenue Forecast ($bn), 2017-2027
  • Figure 2.2 Global Biosimilar Market Drivers, 2017
  • Figure 2.3 Global Biosimilar Market Restraints, 2017
  • Figure 4.1 Sandoz: Biosimilar Products Revenue Forecast ($bn), 2017-2027
  • Figure 4.2 Teva Pharmaceuticals: Biosimilar Products Revenue Forecast ($bn), 2017-2027
  • Figure 4.3 Mylan Pharmaceuticals: Biosimilar Products Revenue Forecast ($bn), 2017-2027
  • Figure 5.1 S3Bio Pharmaceuticals: Biosimilar Products Revenue Forecast ($bn), 2017-2027
  • Figure 6.1 Biocon: Biosimilar Products Revenue Forecast ($bn), 2017-2027
  • Figure 9.1 SWOT Analysis of the Biosimilars Market, 2017
  • Figure 9.2 STEP Analysis of the Biosimilars Market, 2017

List of Tables

  • Table 2.1 Global Biosimilar Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2021
  • Table 2.2 Global Biosimilar Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2021-2027
  • Table 2.3 Finalised US FDA Biosimilar Guidelines
  • Table 3.1 Humira Biologic Analysis, 2017
  • Table 3.2 Remicade Biologic Analysis, 2017
  • Table 3.3 Enbrel Biologic Analysis, 2017
  • Table 3.4 Aranesp: Biologic Analysis, 2017
  • Table 3.5 Rituxan: Biologic Analysis, 2017
  • Table 4.1 Sandoz: Company Overview, 2017
  • Table 4.2 Sandoz: Biosimilars Product Portfolio, 2017
  • Table 4.3 Sandoz: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 4.4 Sandoz: Biosimilar Products Forecast: Revenue ($bn), AGR (%),
  • Table 4.5 Sandoz: Biosimilar Developments Overview, 2017
  • Table 4.6 Teva: Company Overview, 2017
  • Table 4.7 Teva: Biosimilars Overview, 2017
  • Table 4.8 Teva Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 4.9 Teva Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 4.10 Hospira: Company Overview, 2017
  • Table 4.11 Hospira: Company Overview, 2017
  • Table 4.12 Hospira: Biosimilar Developments Overview, 2017
  • Table 4.13 Stada Arzneimittel: Company Overview, 2017
  • Table 4.14 Stada Arzneimittel: Biosimilars Overview, 2017
  • Table 4.15 Stada Arzneimittel: Biosimilar Developments Overview, 2017
  • Table 4.16 Mylan: Company Overview, 2017
  • Table 4.17 Mylan: Biosimilars Overview, 2017
  • Table 4.18 Mylan Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 4.19 Mylan Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 4.20 Mylan: Biosimilar Developments Overview, 2017
  • Table 4.21 Impax Laboratories: Company Overview, 2017
  • Table 4.22 Bristol-MyersSquibb: Company Overview, 2017
  • Table 4.23 Merck & Co.: Company Overview, 2017
  • Table 4.24 Merck & Co.: Biosimilars Product Pipeline, 2017
  • Table 4.25 Eli Lilly: Company Overview, 2017
  • Table 4.26 Eli Lilly: Biosimilars Product Portfolio, 2017
  • Table 4.27 BioXpress Therapeutics: Company Overview, 2017
  • Table 4.28 Medice Arzneimittel Pütter: Company Overview, 2017
  • Table 4.29 Finox Biotech: Company Overview, 2017
  • Table 5.1 3SBio: Company Overview, 2017
  • Table 5.2 3SBio: Biosimilars Overview, 2017
  • Table 5.3 3SBio Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 5.4 3SBio Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 5.5 3SBio: Biosimilar Developments Overview, 2017
  • Table 5.6 Qilu Pharmaceutical: Company Overview, 2017
  • Table 5.7 Qilu Pharmaceutical: Biosimilars Overview, 2017
  • Table 5.8 Qilu Pharmaceutical: Biosimilar Developments Overview, 2017
  • Table 5.9 Shanghai Fosun: Company Overview, 2017
  • Table 5.10 Shanghai Fosun: Biosimilars Overview, 2017
  • Table 5.11 Shanghai Fosun: Biosimilar Developments Overview, 2017
  • Table 5.12 Tonghua Dongbao: Company Overview, 2017
  • Table 5.13 Tonghua Dongbao: Biosimilars Overview, 2017
  • Table 5.14 Tonghua Dongbao: Biosimilar Developments Overview, 2017
  • Table 5.15 Beijing ShuangLu: Company Overview, 2017
  • Table 5.16 Beijing ShuangLu: Biosimilars Overview, 2017
  • Table 5.17 Beijing ShuangLu: Biosimilar Developments Overview, 2017
  • Table 5.18 Shanghai CP Guojian: Company Overview, 2017
  • Table 5.19 Zhejiang Hisun: Company Overview, 2017
  • Table 5.20 Innovent Biologics: Biosimilars Overview, 2017
  • Table 5.21 Shanghai Celgen Biopharmaceutical: Company Overview, 2017
  • Table 6.1 Biocon: Company Overview, 2017
  • Table 6.2 Biocon: Biosimilars Product Portfolio, 2017
  • Table 6.3 Biocon: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 6.4 Biocon: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 6.5 Biocon: Biosimilars Pipeline, 2017
  • Table 6.6 Dr. Reddy's Laboratories: Company Overview, 2017
  • Table 6.7 Dr. Reddy's Laboratories: Biosimilar Products, 2017
  • Table 6.8 Dr. Reddy's Laboratories: Biosimilars Pipeline, 2017
  • Table 6.9 Wockhardt: Company Overview, 2017
  • Table 6.10 Wockhardt: Biosimilar Products, 2017
  • Table 6.11 Wockhardt: Biosimilars Pipeline, 2017
  • Table 6.12 Zydus Cadila: Company Overview, 2017
  • Table 6.13 Zydus Cadila: Biosimilars Product Portfolio, 2017
  • Table 6.14 Zydus Cadila: Biosimilars Pipeline, 2017
  • Table 6.15 Ranbaxy: Company Overview, 2017
  • Table 6.16 Ranbaxy: Biosimilars Product Portfolio, 2017
  • Table 6.17 Zenotech: Biosimilars Pipeline, 2017
  • Table 6.18 Reliance Life Sciences: Company Overview, 2017
  • Table 6.19 Reliance Life Sciences: Biosimilar Products, 2017
  • Table 6.20 Reliance Life Sciences: Biosimilars Pipeline, 2017
  • Table 6.21 Intas Biopharmaceuticals: Company Overview, 2017
  • Table 6.22 Intas Biopharmaceuticals: Biosimilar Products Portfolio, 2017
  • Table 6.23 Intas Biopharmaceuticals: Biosimilars Pipeline, 2017
  • Table 6.24 Emcure Pharmaceuticals: Company Overview, 2017
  • Table 6.25 Shreya Life Sciences: Company Overview, 2017
  • Table 6.26 Cipla: Company Overview, 2017
  • Table 6.27 Shantha Biotechnics: Company Overview, 2017
  • Table 7.1 Probiomed: Company Overview, 2017
  • Table 7.2 Probiomed Biosimilars Product Portfolio, 2017
  • Table 7.3 Biosidus: Company Overview, 2017
  • Table 7.4 Biosidus: Biosimilars Product Portfolio, 2017
  • Table 7.5 Biosidus: Biosimilars Pipeline, 2017
  • Table 7.6 Amega Biotech: Company Overview, 2017
  • Table 7.7 Amega Biotech: Biosimilars Product Portfolio , 2017
  • Table 7.8 Bionovis: Company Overview, 2017
  • Table 7.9 Orygen Biotechnologia: Company Overview, 2017
  • Table 7.10 Recepta: Company Overview, 2017
  • Table 8.1 Celltrion: Company Overview, 2017
  • Table 8.2 Celltrion: Biosimilars Overview, 2017
  • Table 8.3 Celltrion: Biosimilars Product Pipeline, 2017
  • Table 8.4 LG Life Sciences: Company Overview, 2017
  • Table 8.5 LG Life Sciences: Biosimilars Product Portfolio, 2017
  • Table 8.6 LG Life Sciences: Biosimilars Pipeline, 2017
  • Table 8.7 Dong-A: Company Overview, 2017
  • Table 8.8 Dong-A: Biosimilar Product Portfolio, 2017
  • Table 8.9 Dong-A: Biosimilar Pipeline, 2017
  • Table 8.10 Bioton: Company Overview, 2017
  • Table 8.11 Bioton: Biosimilars Product Portfolio, 2017
  • Table 8.12 Biocad: Company Overview, 2017
  • Table 8.13 Biocad: Biosimilars Product Portfolio, 2017
  • Table 8.14 Biocad: Biosimilars Pipeline, 2017
  • Table 8.15 Gedeon-Richter: Company Overview, 2017
  • Table 8.16 Egis Pharmaceuticals: Company Overview, 2017
  • Table 8.17 JCR Pharmaceuticals: Company Overview, 2017
  • Table 8.18 Nippon Kayaku: Company Overview, 2017
  • Table 8.19 Fujifilm Kyowa Kirin Biologics: Company Overview, 2017
  • Table 8.20 Daiichi Sankyo: Company Overview, 2017

Companies Listed

  • Abbott Laboratories
  • Abbvie
  • Actavis
  • Alvogen
  • Ambrx
  • Amega Biotech
  • Amerigen Pharmaceuticals
  • Amgen
  • ANVISA
  • Apotex Inc
  • ASKA Pharmaceuticals
  • AstraZeneca
  • Baxter
  • Beijing ShuangLu Pharmaceuticals
  • Bio Technology General Corporation
  • Bioceuticals
  • Biocon
  • Biogen Idec
  • Biogenerics Arzneimittel
  • BioMab
  • Bionovis
  • BioPartners
  • Biosidus
  • Bioton
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Catalent Pharma Solutions
  • Cell Pharm
  • Celltrion
  • Ciba-Geigy
  • Cipla Biotech
  • CITIC Group
  • Coherus Biosciences
  • Daiichi Sankyo
  • Dainippon Sumitomo Pharma
  • DM Bio plant
  • Dong-A
  • Dr. Reddy's Laboratories
  • Egis Pharmaceutical
  • Eisai
  • Eli Lilly
  • Emcure Pharmaceuticals
  • Epirus Pharmaceutical
  • Ferring Pharmaceuticals
  • Finox Biotech
  • Fujifilm Kyowa Kirin Biologics
  • Gan & Lee Pharmaceutical
  • Gedeon Richter
  • Genentech
  • GeneriCo, LLC
  • GeneScience
  • Gland Pharma
  • GSK
  • Hangzhou Jiuyuan Gene Engineering Co
  • Hexal
  • Hospira
  • Hualida Biotech
  • Impax Laboratories Inc
  • Innovent Biologics
  • Intas Biopharmaceuticals
  • Janssen Biotech
  • JCR Pharmaceuticals
  • Johnson & Johnson
  • Kwizda Pharma
  • LG
  • LG Chem Investment (LGCI)
  • LG Life Sciences
  • MabPharm
  • Marvel Life Sciences
  • Medice Arzneimittel
  • Meiji Seika Pharmaceutical
  • Merck KGa
  • Merck Serono
  • Mitsubishi Tanabe
  • Momenta Pharmaceuticals
  • Mylan
  • Nippon Kayaku
  • NovaQuest
  • Novartis
  • Novo Nordisk
  • Orygen Biotecnologia
  • Owen Mumford
  • Pfizer
  • Pilva
  • Probiomed
  • Qilu Pharmaceutical
  • Ranbaxy
  • Ratiopharm
  • Recepta
  • Reliance Life Sciences
  • Richter-Helm BioTec GmbH& Co. KG
  • Roche
  • Royal DSM
  • Samsung Bioepis
  • Sandoz
  • Sanofi
  • Sanwa Kenkyusho Co. Ltd
  • Savient Pharmaceuticals
  • Shandong Kexing Pharma
  • Shanghai Celgen Biopharmaceuticals
  • Shanghai CP Guojian
  • Shanghai Fosun Pharmaceutical
  • Shanghai Henlius Biotech
  • Shanghai Lansheng Guojian Pharmaceutical Co. Ltd
  • Shanghai Stock Exchange
  • Shantha Biotechnics
  • Shenyang Sunshine (3SBio)
  • Shreya Life Sciences
  • Sicor
  • Sidus Pharmaceutical Group
  • Stada Arzneimittel
  • Sumitomo Pharmaceuticals
  • Sun Pharma
  • Takeda
  • Teva
  • Tonghua Dongbao
  • WHO
  • Wockhardt
  • Xiamen Amoytop Biotech
  • Ypsomed
  • Zhejiang Hisun
  • Zydus Cadila

List of Organisations

  • Biopharmaceuticals and Herbal Medicines Bureau South Korea
  • Central Drugs Standard Control Organisation
  • Centre for Drug Evaluation
  • China National Pharmaceutical Group (Sinopharm)
  • Chinese Food & Drug Administration (CFDA)
  • Committee for Medicinal Products for Human Use (CHMP)
  • European Medicine Agency (EMA)
  • European Union (EU)
  • Financier of Studies and Projects (FINEP)
  • US Food and Drug Administration (FDA)
  • International Labour Organization (ILO)
  • Korean Food and Drug Administration
  • Ludwig Institute for Cancer Research
  • Medicine and Healthcare Products Regulatory Agency (MHRA)
  • Ministry of Health, Labor and Welfare (MHLW)
  • National Autonomous University of Mexico (UNAM)
  • National Council for Science and Technology (CONACyT)
  • National Health Service (UK)
  • Therapeutic Goods Administration (TGA)
  • World Health Organisation (WHO)
Back to Top